BI Spotlight
New Aptivus® (tipranavir) Oral Solution Approved for
Treatment-Experienced Pediatric and Adolescent HIV Patients
Ridgefield, CT - June 24, 2008 --
The U.S. Food and Drug Administration (FDA) granted approval of Aptivus® (tipranavir) capsules/oral solution for use in treatment-experienced pediatric patients between the ages of 2-18 infected with HIV-1.
Please see full Prescribing Information, including boxed warning for APTIVUS, at www.aptivus.com.
Learn More